Medisix Therapeutics

What Medisix Therapeutics does

Medisix Therapeutics is a Singapore-based, privately held biopharmaceutical company founded in 2016 by Professor Dario Campana (creator of the anti-CD19-41BB-CD3z CAR underpinning Kymriah, the first FDA-approved CAR T-cell therapy). The company develops proprietary T-cell therapies for patients with complex and rare T-cell malignancies and, more recently, autoimmune diseases driven by T-cell autoreactivity. MediSix's core differentiator is its PEBL (Protein Expression BLocker) platform, which intracellularly traps target proteins in the endoplasmic reticulum and/or Golgi to prevent their expression on the cell surface, thereby overcoming the fratricide problem that has limited CAR T-cell therapy in T-cell cancers. The pipeline comprises PCART7 (anti-CD7 CAR T-cells targeting T-ALL, T-LL, and AML), PCART3 (targeting PTCL and CTCL), and an allogeneic (off-the-shelf) PCART7 program enabled by PEBL-mediated suppression of TCR/CD3 expression. A bi-cistronic vector enables single-step co-expression of PEBL and CAR proteins, streamlining GMP manufacturing compatible with existing CAR T-cell production infrastructure.

Medisix operates a traditional clinical-stage biotech business model: pre-revenue today, it pursues IND-enabling activities and Phase 1 clinical development (with early clinical experience in Singapore T-ALL patients during 2019-2020 and a Phase 1 / IND targeted for 2023) en route to eventual regulatory approval and commercialization through hospital pharmacies and specialized treatment centers. The customer base today consists of clinical trial sites in Singapore; the future paying customer is the specialty hematology-oncology treatment center. Capital partners include Temasek, Lightstone Ventures, Osage University Partners, the National University of Singapore, and Cancer Ventures Boston. The company's go-to-market relies on scientific publications (including the 64th ASH Annual Meeting in December 2022), conference presentations, press releases, and an investor relations presence rather than enterprise field sales.

The company is venture-backed with 11-50 employees headquartered at 11 Biopolis Way in Singapore's Biopolis biomedical hub. Key strategic assets include the proprietary PEBL platform, foundational CAR T-cell patents via Prof. Campana, a 2022 antibody discovery collaboration with Twist Bioscience, and a senior team combining scientific founders (Prof. Campana) with pharmaceutical operators (CEO Andrew Bruce, 36 years of pharma experience). No commercial product, revenue, or subsequent funding round beyond the 2018 Series A is disclosed, and clinical activity to date is concentrated in Singapore.

Name

Medisix Therapeutics

Legal name

MediSix Therapeutics

Website

https://medisixtx.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Medisix Therapeutics is a Singapore-based, clinical-stage biotech founded in 2016 that develops proprietary PEBL-engineered CAR T-cell therapies to treat rare T-cell malignancies (T-ALL, T-LL, PTCL, CTCL, AML) and autoimmune diseases, and is pre-revenue pursuing IND-enabling studies and Phase 1 trials.

Ownership category

akta.pro rank

Product category

Cell Therapy / CAR T-cell Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAAABAC

CAR-T & TCR-T Therapies

Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

SECONDARYHLAAABAL

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)

Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

SECONDARYHLAAANAK

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)

Healthcare & Life Sciences/Biotechnology & Biologics/Precision Medicine Solutions

Keywords

• Cell therapy platforms
• CAR T-cell therapies
• T-cell malignancy treatments
• Protein expression blockers
• Allogeneic cell therapies

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Biopharmaceutical / Cell Therapy Commercialization: MediSix is a pre-revenue biotech company developing novel T-cell therapies. Revenue will be generated through the commercialization of CAR T-cell therapy products following regulatory approval. The company is in the clinical development stage with multiple pipeline programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Medisix Therapeutics is a clinical-stage biotechnology company developing proprietary CAR T-cell therapies built on its PEBL (Protein Expression BLocker) technology platform. The company focuses on treating T-cell malignancies including T-cell acute lymphoblastic leukemia (T-ALL), T-cell lymphoblastic lymphoma (T-LL), peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), and acute myeloid leukemia (AML), as well as selected autoimmune diseases. PEBL prevents fratricide (self-killing) of CAR T-cells without gene editing, enabling single-step GMP-compatible manufacturing of both autologous and allogeneic products.

Product overview

MediSix Therapeutics is a biopharmaceutical company developing proprietary T-cell therapies for cancer and autoimmune diseases. The core technology platform is PEBL (Protein Expression BLocker), which intracellularly traps and downregulates surface proteins to enhance immune cell function. The product portfolio includes PCART7 (anti-CD7 CAR T-cell therapy for T-ALL, T-LL, and AML), PCART3 (for PTCL and CTCL), and Allogeneic PCART7 (off-the-shelf allogeneic therapy). PEBL-CAR technology combines PEBL with CARs to overcome industry challenges like fratricide in T-cell malignancies without requiring gene editing.

Differentiator

Problem solved

Functional benefit

Products and services

• PCART7
• PCART3
• Allogeneic PCART7

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Twist BiosciencecoreStrategic or Co-development Partner · 1 January 2022Twist Bioscience signed an antibody discovery collaboration with MediSix Therapeutics in 2022 to develop T-cell therapies. This collaboration leverages Twist Bioscience's antibody discovery capabilities with MediSix's proprietary PEBL-CAR T-cell technology platform to advance novel T-cell therapy candidates.
• DotBiominorStrategic or Co-development PartnerDotBio is listed as a strategic partnership on MediSix's About page. The nature and scope of the collaboration is not detailed in available sources.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Nkarta Therapeutics: Nkarta was co-founded by Professor Dario Campana (MediSix's scientific founder) and develops engineered NK cell therapies for cancer — making it the closest peer by founder lineage and overlapping cell therapy modality.
• Allogene Therapeutics: Pioneer of off-the-shelf allogeneic CAR-T cell therapies. Directly comparable to MediSix's allogeneic PCART7 program in approach (healthy donor T-cells engineered for off-the-shelf use) and target indications in hematologic cancers.
• CRISPR Therapeutics: Develops gene-edited cell therapies including allogeneic CAR-T programs using CRISPR/Cas9. Directly comparable to MediSix as a competing approach (gene editing vs. PEBL protein blocking) for engineering next-generation CAR-T cells.
• Adicet Bio: Develops gamma-delta CAR-T cell therapies with active programs in CD7 CAR-T for T-cell malignancies — the most direct head-to-head competitor to MediSix's PCART7 in the T-cell cancer indication.
• Caribou Biosciences: Develops allogeneic CAR-T cell therapies using CRISPR-based gene editing. Comparable to MediSix in approach (engineered allogeneic cell therapy) and target indications in B-cell malignancies, with overlapping cell engineering technology.
• Cellectis: Pioneer of TALEN-based gene editing for allogeneic CAR-T cell therapies, with active programs in T-cell malignancies. Directly comparable to MediSix in the gene-engineering-vs-PEBL debate and the T-cell malignancy indication space.
• Precision BioSciences: Develops allogeneic CAR-T therapies using its proprietary ARCUS gene editing platform. Comparable to MediSix in allogeneic cell therapy approach and competing indication set in hematologic malignancies.
• Adaptimmune: Develops engineered T-cell receptor (TCR-T) therapies for solid tumors and hematologic malignancies. Comparable to MediSix in T-cell receptor engineering expertise and cell therapy modality, with overlapping scientific leadership in cell engineering.

Emerging players

• Century Therapeutics: Develops iPSC-derived allogeneic cell therapies with gene editing to prevent rejection — a complementary approach to MediSix's allogeneic platform with potential overlap in indications and engineering strategies.
• CytoMed Therapeutics: Singapore-based peer developing allogeneic gamma-delta CAR-T cell therapies, including CD7-directed programs for T-cell malignancies. Direct regional competitor to MediSix with overlapping technology approach and indication focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medisix Therapeutics